Fig. 3

In vivo validation of the combination of venetoclax and FLT3 inhibitors a NSG mice were engrafted with MOLM-13 cells expressing luciferase and treated with vehicle, 50 mg/kg midostaurin, 75 mg/kg venetoclax, or both midostaurin and venetoclax. b Kaplan–Meier analysis of the mouse survival. The log-rank test was used to compare survival between groups of interest. Comparisons of single agent vs. combo were considered primary; all comparisons versus vehicle were considered secondary. p values were adjusted for multiple comparisons using Holm’s method for the primary and secondary comparisons separately. c IVIS imaging shows changes in luciferase signal over 3 weeks. d NCG mice were engrafted with MOLM-13 cells expressing luciferase and treated with vehicle, 30 mg/kg gilteritinib, 75 mg/kg venetoclax, or both gilteritinib and venetoclax. e Kaplan–Meier analysis of the mouse survival. Statistics were performed as described for the midostaurin/venetoclax experiment. f IVIS imaging shows changes in luciferase signal over 5 weeks